What do systematic reviews say?

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 350 participants
  High

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

The review found no eligible studies for this question.

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 238 participants
  Moderate

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 61 participants
  Moderate

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Low

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Low

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Low

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i probably leads to lower improvement in WHO functional class compared with placebo (moderate certainty).

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  OR 0.53 [0.32, 0.87]
  3 studies · 285 participants
  Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 284 participants
  Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i showed no clear difference in mortality compared with placebo (moderate certainty).

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  OR 1.27 [0.28, 5.8]
  3 studies · 286 participants
  Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 52 participants
  Low

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 130 participants
  Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 96 participants
  Moderate

Supervised maintenance programme following pulmonary rehabilitation vs usual care

The review found no eligible studies for this question.

• Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Supervised maintenance programme following pulmonary rehabilitation vs usual care

• Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 258 participants
  Low

Supervised maintenance programme following pulmonary rehabilitation vs usual care

• Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 639 participants
  Low

Supervised maintenance programme following pulmonary rehabilitation vs usual care

Supervised maintenance programme following pulmonary rehabilitation showed no clear difference in hospital admission (all‐cause): number of people admitted to hospital compared with usual care (low certainty).

• Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive… 2021 · Cochrane Headline outcomes only
  OR 0.71 [0.14, 3.69]
  2 studies · 142 participants
  Low
• Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 332 participants
  GRADE not reported

Supervised maintenance programme following pulmonary rehabilitation vs usual care

Supervised maintenance programme following pulmonary rehabilitation showed no clear difference in exacerbation: number of people experiencing one or more exacerbation compared with usual care (low certainty).

• Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive… 2021 · Cochrane Headline outcomes only
  OR 0.73 [0.26, 2.02]
  3 studies · 281 participants
  Low

Supervised maintenance programme following pulmonary rehabilitation vs usual care

• Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 342 participants
  GRADE not reported

Supervised maintenance programme following pulmonary rehabilitation vs usual care

Supervised maintenance programme following pulmonary rehabilitation showed no clear difference in mortality compared with usual care (moderate certainty).

• Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive… 2021 · Cochrane Headline outcomes only
  OR 0.73 [0.36, 1.51]
  6 studies · 755 participants
  Moderate